Success Metrics

Clinical Success Rate
87.0%

Based on 60 completed trials

Completion Rate
87%(60/69)
Active Trials
3(4%)
Results Posted
82%(49 trials)
Terminated
9(11%)

Phase Distribution

Ph phase_4
5
6%
Ph early_phase_1
1
1%
Ph not_applicable
5
6%
Ph phase_1
11
13%
Ph phase_2
45
54%
Ph phase_3
15
18%

Phase Distribution

12

Early Stage

45

Mid Stage

20

Late Stage

Phase Distribution82 total trials
Early Phase 1First-in-human
1(1.2%)
Phase 1Safety & dosage
11(13.4%)
Phase 2Efficacy & side effects
45(54.9%)
Phase 3Large-scale testing
15(18.3%)
Phase 4Post-market surveillance
5(6.1%)
N/ANon-phased studies
5(6.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.9%

60 of 77 finished

Non-Completion Rate

22.1%

17 ended early

Currently Active

3

trials recruiting

Total Trials

84

all time

Status Distribution
Active(3)
Completed(60)
Terminated(17)
Other(4)

Detailed Status

Completed60
Terminated9
Withdrawn8
unknown3
Recruiting2
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
84
Active
3
Success Rate
87.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.2%)
Phase 111 (13.4%)
Phase 245 (54.9%)
Phase 315 (18.3%)
Phase 45 (6.1%)
N/A5 (6.1%)

Trials by Status

suspended11%
terminated911%
unknown34%
withdrawn810%
active_not_recruiting11%
completed6071%
recruiting22%

Recent Activity

Clinical Trials (84)

Showing 20 of 84 trialsScroll for more
NCT04404881Phase 2

Bevacizumab In Hereditary Hemorrhagic Telangiectasia

Active Not Recruiting
NCT07244705Phase 1

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

Recruiting
NCT07012954Phase 1

ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

Recruiting
NCT01083966Phase 1

Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma

Suspended
NCT00555594Phase 2

Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

Completed
NCT00390026Phase 3

The Avastin vs Visudyne for Neovascular AMD Study

Withdrawn
NCT00870636

Use of Pan-vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)

Unknown
NCT00642577Phase 3

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.

Completed
NCT01331616Early Phase 1

Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab

Withdrawn
NCT02256800Not Applicable

Escalated Dose of Irinotecan in mCRC

Completed
NCT01201850Not Applicable

The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors

Terminated
NCT00271505Phase 2

Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer

Completed
NCT00643565Phase 2

A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.

Completed
NCT00846612Phase 1

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

Completed
NCT01663727Phase 3

Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Completed
NCT01069627Phase 2

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma

Completed
NCT00577109Phase 2

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.

Withdrawn
NCT00642603Phase 2

A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer

Terminated
NCT00932152Phase 2

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

Terminated
NCT01418222Phase 2

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Completed

Drug Details

Intervention Type
DRUG
Total Trials
84